(BIO) Bio-Rad Laboratories - Ratings and Ratios

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a global leader in the development, manufacture, and distribution of life science research and clinical diagnostic products. The company operates through two primary segments: Life Science and Clinical Diagnostics. The Life Science segment provides instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids. These products are essential for biopharmaceutical manufacturing, quality control processes, food safety testing, and science education. The Clinical Diagnostics segment offers test systems, informatics, test kits, and quality controls for hospitals, diagnostic reference laboratories, and physician office laboratories. Bio-Rads products are distributed through a combination of direct sales force and third-party distributors, agents, brokers, and resellers. Founded in 1952 and headquartered in Hercules, California, the company has established a strong presence in the United States, Europe, Asia, Canada, and Latin America, with a robust portfolio that supports advancements in healthcare and scientific research.

Technically, BIO is currently trading at 249.74, with a 20-day SMA of 240.76 and a 50-day SMA of 255.51. The stock is below its 200-day SMA of 314.14, indicating a bearish trend. The Average True Range (ATR) of 10.63 suggests moderate volatility. From a fundamental perspective, Bio-Rad has a market capitalization of 6.865B USD, with a forward P/E ratio of 26.74, reflecting expectations of future earnings growth. The price-to-book ratio of 1.05 indicates the stock is fairly valued relative to its book value, while the price-to-sales ratio of 2.68 suggests moderate valuation. However, the negative return on equity (RoE) of -28.07 raises concerns about profitability and efficiency in generating returns from shareholders equity.